Acute joint inflammation case study: Mr. Y, great toe pain

The diagnosis is the easy part of this case and the medication list is where the marks are. Severe acute pain in the right great toe, a serum uric acid of 10.9, and a sedimentation rate of 93 point clearly at acute gout — podagra is the classic first presentation. Note also what the white cell count is doing: **8,200 with a normal differential**, which argues against septic arthritis, the differential that actually matters here because missing it is dangerous. Saying why you excluded septic arthritis, rather than only naming gout, is what turns a correct answer into a reasoned one. A hot, acutely painful single joint is a septic joint until proven otherwise, so the exclusion is not a formality; it is the safety step, and the case has given you exactly the value that lets you make it.

Now look at what he is taking. Mr Y is on **HCTZ 25 mg daily** for hypertension, and thiazide diuretics are a recognised cause of hyperuricaemia — they reduce renal urate excretion. His antihypertensive is a plausible contributor to the condition you are being asked to treat. That observation is sitting in plain sight in the case and most answers walk past it, because the medication list reads as background rather than as evidence. It changes the long-term question completely: managing this patient may involve reconsidering the diuretic, not only adding a urate-lowering drug on top of it. Say it explicitly and cite it, because a marker reading a plan that adds a second drug while leaving the first cause untouched will notice the omission before anything else in the paper.

The two pharmacologic questions are deliberately separate and the drug classes do not overlap, which is the second thing weaker answers blur. **Acute management** targets the inflammation — NSAIDs, colchicine, or corticosteroids, chosen according to comorbidity. **Long-term management** targets the urate level itself with urate-lowering therapy, and the standard caution is that starting it during an acute attack can precipitate or prolong one unless prophylactic cover is given. Presenting allopurinol as the treatment for the acute attack is a clinically wrong answer that reads plausibly, and it is the single most likely error in this case. The sequencing matters as much as the choice: settle the attack first, then start prevention once the joint is quiet, with cover during the transition.

His renal function is in the case for a reason too. A **serum creatinine of 1.2** is not dramatic but it constrains both plans: NSAID choice and duration in a patient already on an ACE inhibitor and a diuretic carries real renal risk, and urate-lowering dosing is adjusted to renal function. Every number in a case like this is there because it changes something, so the discipline that pays is to go through them one at a time and ask what each one rules in, rules out, or constrains. The random glucose of 117 and the haemoglobin of 13.4 are worth a sentence each for the same reason. Working through the numbers in order also stops you writing an answer that would be identical for any patient with a raised urate, which is what the case format is designed to test.

Two structural points. Both pharmacologic questions require a justification **with a citation from a peer-reviewed source**, so that is at least two citations doing argumentative work rather than decorating the reference list — cite the guideline or trial that supports the choice, not a general pharmacology text. And the fourth question, on patient education, asks for the key elements covering **both** the acute and the chronic plans. That is where the diuretic observation pays off again: an education plan that explains why a long-term drug is taken when the toe no longer hurts, and what to do at the next flare, is addressing the actual reason urate-lowering therapy fails in practice. Adherence is the whole difficulty with urate-lowering therapy, because the drug prevents something the patient cannot feel, and the education question is really asking whether you understand that.